Mapping the human mucosal immune response to respiratory viruses

Mapping the human mucosal immune response
to respiratory viruses

Conventionally, human immune responses have been extensively characterized using blood. Immune cells, though abundant in blood, are also found in various tissues in varying numbers and with locally relevant functional specification. Assessing immune responses in the airways over the course of infection and convalescence is critical to comprehensively mapping immunity to respiratory viral infections including influenza and SARS-CoV-2.

In a study recently published in eLife, Sindhu Vangeti, PhD, and colleagues at the Icahn School of Medicine at Mount Sinai, demonstrated that innate immune cells, like monocytes and dendritic cells, possess unique dynamics defined by location and pathogen. In addition to characterizing immune cells in blood, the team also investigated immune cell distribution and function in the human nasopharynx.

Learn about:

  • Monocytes and dendritic cells in human respiratory viral infections.
  • Studying immune responses in the human airways.
  • Integrating state-of-the-art platforms into conventional study design.

Image of Sindhu Vangeti

Sindhu Vangeti, PhD

Sindhu Vangeti, PhD, is a postdoctoral fellow in Irene Ramos’s viral immunology team in the Stuart C. Sealfon lab at the Icahn School of Medicine at Mount Sinai. Currently, her research focuses on mapping the epigenetic fingerprint of influenza/SARS-CoV-2 exposure and studying mechanisms that lead to durability of vaccine-induced immunity. Dr. Vangeti obtained her doctorate in 2019 at the Karolinska Institutet in the lab of Anna Smed Sörensen, studying human immune responses to influenza and hantavirus infections.

Mapping the human mucosal immune response to respiratory viruses

A presentation by Sindhu Vangeti, PhD

More resources for immunology research

What can proteomics teach us about infectious disease?

Watch webinar

Tech Note:
SomaScan Assay v4.1 signaling in mouse plasma


Case studies:
Massive-scale proteomics for COVID-19

Learn more

White paper:
COVID-19 and the SomaScan® Platform


Search our publications viewer

Search our extensive database of peer-reviewed research on the use of the SomaScan® Platform by entering keywords to narrow your search, such as influenza, COVID, or respiratory.

See publications

Share with colleagues

More webinars

WebinarCorrelation of a Nonalcoholic Steatohepatitis Proteomic Test with Clinical Outcomes

In this webinar, Anne Minnich, PhD, biomarker consultant at Bristol Myers Squibb, presents research on the use of the new SomaSignal(TM) NASH bundle test in a recently completed clinical trial.

Learn more

WebinarHarnessing AI and proteomics for glioblastoma

The development and advancement of aptamer technology opens vast possibilities for unlocking the biocomplexity available within proteomics. Learn more about the powerful tools that are enabling the discovery and validation of clinically relevant biomarkers and accelerating research.

Learn more

WebinarAccelerating precision medicine of cancer with SomaScan® proteomics

Proteomics has emerged as the next frontier in precision medicine, and several innovative proteomics platforms have been developed to drive biomarker discovery. We [at Beth Israel Deaconess Medical Center] are using the currently most comprehensive proteomics technology -- the SomaScan Platform, which measures 7,000 proteins -- to discover and independently validate diagnostic, predictive, and prognostic biomarkers for various cancers.

Learn more